Market Research on Chinese Patent Medicine in China 2016-2021

  • ID: 4311185
  • Report
  • Region: China
  • 41 pages
  • ASKCI Consulting Co., Ltd
1 of 4
In 2015, there were about 1,600 enterprises above scale in the Chinese patent medicine industry in China. The total assets of the industry was RMB596 billion, rising by about 10%. The market revenue was RMB615 billion, rising by 6%. The total profit was RMB67 billion, rising by 13%.

In 2015, the output of the Chinese patent medicine in China was 3.76 million tonnes, rising by 2%. At present, the Chinese medicine has stepped into a road of virtuous cycle, namely from prevention to cure and then from cure to prevention.

Since China has invested more in the Chinese medicine industry, the industry has been developing into modernization. The modern Chinese patent medicines market has better quality and clinical effect, with “special effects” to some diseases.

The Chinese patent medicine market is one of the three pillar industries of the Chinese medicine industry. For a better construction and development, the government has published a series of supporting policies, which will make an explosive increase in the Chinese patent industry for the next few years.

Please note that this report takes 1-2 business days for delivery.
Note: Product cover images may vary from those shown
2 of 4
Executive Summary

Methodology

1 Development Environment of Chinese Patent Medicine Industry in China
1.1 Economy Environment
1.2 Policy Environment
1.3 Social Environment

2 Development Status of Chinese Patent Medicine Industry in China, 2011-2015
2.1 Industrial Scale
2.2 Operating Efficiency
2.3 Concentrate Ratio

3 Analysis of Key Manufacturers of Chinese Patent Medicine in China
3.1 Tasly Pharmaceutical Group Co., Ltd.
3.2 Tianjin Zhongxin Pharmaceutical Group Corporation Limited
3.3 Hunan Fangsheng Pharmaceutical Co., Ltd.
3.4 Shanghai Kaibao Pharmaceutical Co., Ltd.
3.5 Zhejiang Xinguang Pharmaceutical Limited Liability Company
3.6 Xi’an Wanlong Pharmaceutical Co., Ltd.
3.7 Buchang Pharmaceuticals
3.8 Teyi Pharmaceutical Group Co., Ltd.
3.9 Heilongjiang ZBD Pharmaceutical Co., Ltd.
3.10 Lanzhou Foci Pharmaceutical Co., Ltd.

4 Forecast and Investment Strategy of Chinese Patent Medicine Industry in China, 2016-2021
4.1 Forecast
4.2 Investment Strategy
4.2.1 Industrial Policies in China
4.2.2 Law of Industry Development
4.2.3 Resources and Capacity of Enterprises
4.2.4 Predictable Strategic Positioning

List of Figures
Figure 1 GDPs of China, 2011-2016
Figure 2 Fixed asset investments in China, 2011-2016
Figure 3 Total retail sales of consumer goods in China, 2011-2016
Figure 4 Per capita disposable incomes in China, 2011-2016
Figure 5 Total values of import and export of China, 2011-2016
Figure 6 Populations of China, 2011-2015
Figure 7 Distribution of China population by ages at the end of 2015
Figure 8 Urbanization rates of China, 2011-2015
Figure 9 Numbers of above-scale Chinese patent medicine enterprises in China, 2011-2015
Figure 10 Debt ratios of Chinese patent medicine industry in China, 2011-2015
Figure 11 Gross profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 12 Sales profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 13 Asset profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 14 Turnovers of accounts receivable of Chinese patent medicine industry in China, 2011-2015
Figure 15 Turnovers of circulating asset of Chinese patent medicine industry in China, 2011-2015
Figure 16 Turnovers of total asset of Chinese patent medicine industry in China, 2011-2015
Figure 17 Outputs of Chinese patent medicines in China, 2011-2015
Figure 18 Regional output distribution of Chinese patent medicine in China 2015
Figure 19 Business proportions of Tasly Pharmaceutical Group Co., Ltd. in 2015
Figure 20 Business proportions of Tianjin Zhongxin Pharmaceutical Group Corporation Limited in 2015
Figure 21 Business proportions of Hunan Fangsheng Pharmaceutical Co., Ltd. in 2015
Figure 22 Business proportions of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2015
Figure 23 Business proportions of Zhejiang Xinguang Pharmaceutical Limited Liability Company in 2014
Figure 24 Business proportions of Xi’an Wanlong Pharmaceutical Co., Ltd. in 2014
Figure 25 Business proportions of Buchang Pharmaceuticals in 2015
Figure 26 Business proportions of Teyi Pharmaceutical Co., Ltd. in 2015
Figure 27 Business proportions of Heilongjiang ZBD Pharmaceutical Co., Ltd. in 2015
Figure 28 Business proportions of Lanzhou Foci Pharmaceutical Co., Ltd. in 2015

List of Tables
Table 1 GDPs and distributions of China, 2014-2016
Table 2 Related polices to Chinese patent medicine industry in China
Table 3 Population distribution of China in 2015
Table 4 Costs on medical care of urban residents in China, 2011-2015
Table 5 Costs on medical care of rural residents in China, 2011-2015
Table 6 Numbers of health institutions in China, 2013-2016
Table 7 Total assets of Chinese patent medicine industry in China, 2011-2015
Table 8 Sales revenues of Chinese patent medicine industry in China, 2011-2015
Table 9 Total profits of Chinese patent medicine industry in China, 2011-2015
Table 10 Revenues of Tasly Pharmaceutical Group Co., Ltd. by industries and products in 2015
Table 11 Revenues and profits of Tasly Pharmaceutical Group Co., Ltd., 2012-2016
Table 12 Regional revenues of Tasly Pharmaceutical Group Co., Ltd. in 2015
Table 13 Revenues of Tianjin Zhongxin Pharmaceutical Group Corporation Limited by products from Jan. to Sep. in 2016
Table 14 Revenues and profits of Tianjin Zhongxin Pharmaceutical Group Corporation Limited, 2012-2016
Table 15 Revenues of Hunan Fangsheng Pharmaceutical Co., Ltd. by industries and products in 2015
Table 16 Revenues and profits of Hunan Fangsheng Pharmaceutical Co., Ltd., 2012-2016
Table 17 Regional revenues of Hunan Fangsheng Pharmaceutical Co., Ltd. in China 2015
Table 18 Revenues of Shanghai Kaibao Pharmaceutical Co., Ltd. by industries and products in 2015
Table 19 Revenues and profits of Shanghai Kaibao Pharmaceutical Co., Ltd., 2012-2016
Table 20 Regional revenues of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2015
Table 21 Revenues of Zhejiang Xinguang Pharmaceutical Limited Liability Company by products, 2012-2014
Table 22 Revenues and profits of Zhejiang Xinguang Pharmaceutical Limited Liability Company, 2012-2014
Table 23 Revenues of Xi’an Wanlong Pharmaceutical Co., Ltd. by products, 2012-2014
Table 24 Revenues and profits of Xi’an Wanlong Pharmaceutical Co., Ltd., 2012-2014
Table 25 Revenues of Buchang Pharmaceuticals by products, 2013-2016
Table 26 Revenues and profits of Buchang Pharmaceuticals, 2013-2016
Table 27 Revenues of Teyi Pharmaceutical Co., Ltd. by industries and products in 2015
Table 28 Revenues and profits of Teyi Pharmaceutical Co., Ltd., 2012-2016
Table 29 Regional revenues of Teyi Pharmaceutical Co., Ltd. in 2015
Table 30 Revenues of Heilongjiang ZBD Pharmaceutical Co., Ltd., by industries and products in 2015
Table 31 Revenues and profits of Heilongjiang ZBD Pharmaceutical Co., Ltd., 2012-2016
Table 32 Regional revenues of Heilongjiang ZBD Pharmaceutical Co., Ltd. in 2015
Table 33 Revenues of Lanzhou Foci Pharmaceutical Co., Ltd. by industries and products in 2015
Table 34 Revenues and profits of Lanzhou Foci Pharmaceutical Co., Ltd., 2012-2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • Hunan Fangsheng Pharmaceutical Co., Ltd.
  • Shanghai Kaibao Pharmaceutical Co., Ltd.
  • Zhejiang Xinguang Pharmaceutical Limited Liability Company
  • Xi’an Wanlong Pharmaceutical Co., Ltd.
  • Buchang Pharmaceuticals
  • Teyi Pharmaceutical Group Co., Ltd.
  • Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • Lanzhou Foci Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll